Company Intelligence
Veeva Systems is the leading cloud software provider for the global life sciences industry. The company's platform includes Veeva CRM (now Vault CRM), Veeva Vault (content management, regulatory, quality, clinical), and Veeva Data Cloud (commercial and patient data). Veeva holds a dominant position in pharmaceutical and biotech CRM, and has expanded into clinical operations, regulatory affairs, and data solutions. In 2021, the company became a Public Benefit Corporation, committing to balancing stakeholder interests alongside shareholder returns.
Life Sciences Technology
Headquarters
Pleasanton, CA
Employees
~7,000
Revenue
$2.5B (FY2025)
Fiscal Year End
January 31
Founded
2007
Current leadership team based on public filings and announcements.
Peter Gassner
Founder & CEO
Brent Bowman
CFO
Key events and changes that sales teams should know about.
Completed conversion to a Public Benefit Corporation (PBC), making Veeva one of the largest publicly traded PBCs and signaling a long-term commitment to the life sciences industry beyond pure shareholder value.
2025-01
Accelerated the migration from Veeva CRM (built on Salesforce) to Vault CRM (built on Veeva's own platform), a multi-year transition that removes Salesforce dependency and deepens platform lock-in.
2024-11
Q2 FY2025 revenue grew 15% YoY to $676M, with subscription services revenue up 24% driven by strong adoption of Vault and Data Cloud products across enterprise pharma accounts.
2024-09
Life sciences industry dominance continued as Veeva maintained 80%+ market share in pharma CRM, with nearly all top-20 pharmaceutical companies using at least one Veeva product.
2024-07
Expanded R&D and customer success teams to support the Vault CRM migration and growing demand for clinical and regulatory solutions from mid-market biotech firms.
2024-05
Veeva is the dominant vertical software platform in life sciences -- a $2T+ industry with long sales cycles and deep regulatory requirements. With 80%+ market share in pharma CRM and expanding penetration in clinical, regulatory, and quality management, Veeva is the de facto technology backbone for pharmaceutical and biotech companies. Vendors selling into life sciences should understand that Veeva is likely already embedded in their target accounts, and integration with Veeva's ecosystem is often a buying requirement.
The Vault CRM migration away from Salesforce is one of the most significant platform transitions in enterprise SaaS. As Veeva moves thousands of customers from a Salesforce-based CRM to its proprietary Vault platform, the ripple effects extend to integration partners, data vendors, and adjacent technology providers. This transition creates both disruption (breaking existing Salesforce integrations) and opportunity (new integration needs with the Vault platform).
Veeva's January 31 fiscal year end means Q4 runs from November through January, similar to Salesforce. The company's customer base of pharmaceutical and biotech companies often has calendar-year budgets (December fiscal year end), creating a dual budget cycle opportunity. Sales teams should plan engagements around both Veeva's fiscal calendar and their end-customers' budget timelines.
Key competitors based on market analysis and public filings.
Veeva's fiscal year ends on January 31. FY2025 runs from February 1, 2024 through January 31, 2025. Like Salesforce (which shares the same fiscal calendar), the November-January Q4 is typically the strongest quarter for enterprise deal closings.
Veeva Systems generated approximately $2.5 billion in revenue for FY2025, with subscription services growing 20%+ year-over-year. The company has been expanding beyond CRM into clinical, regulatory, quality, and data solutions, diversifying its revenue base across the life sciences value chain.
Veeva converted to a Public Benefit Corporation (PBC) in 2025, following a shareholder vote in 2021. As a PBC, Veeva is legally committed to balancing the interests of all stakeholders -- customers, employees, partners, and the life sciences industry -- alongside shareholder returns. CEO Peter Gassner has described this as a way to build long-term trust with the industry.
Vault CRM is Veeva's new CRM product built entirely on its own Vault platform, replacing the original Veeva CRM that was built on Salesforce's platform. The multi-year migration removes Veeva's dependency on Salesforce and gives the company full control over its technology stack. Most customers are expected to transition by 2025-2026.
Veeva Systems employs approximately 7,000 people globally. The company has been growing its workforce to support R&D for the Vault platform and customer success teams managing the CRM migration for enterprise pharma accounts.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Veeva Systems — updated continuously.
